NEWS
  • March 4, 2021 S1 Biopharma CEO Nick Sitchon to Participate in Maxim Group LLC Review of Late Stage Innovations in Women’s Health
  • December 1, 2019 Dose-Finding Study of Lorexys for Hypoactive Sexual Desire Disorder in Premenopausal Women
  • January 4, 2019 S1 Biopharma to Participate in Panel Discussion on Investment Opportunities in China Hosted by Duane Morris and the Chinese Biopharmaceutical Association
  • January 4, 2019 S1 Biopharma Announces Expanded Analysis of Phase 2a Data on Lorexys™ for Treatment of Hypoactive Sexual Desire Disorder Based on PGIC Scale to be Presented at 2019 ISSWSH/ISSM Joint Meeting
  • December 20, 2018 S1 Biopharma Granted Patents for Lorexys™ in Europe and Asia for Treatment of Hypoactive Sexual Desire Disorder
  • April 5, 2016 MedicalResearch.com | CEO Discusses Lorexys For Female Hypoactive Sexual Desire Disorder
  • February 19, 2016 Pharmaceutical Processing | In Development: HSDD Treatment for Women
  • February 19, 2016 PM360 | Will Lorexys Succeed Where Addyi Flopped?
  • December 8, 2015 S1 Biopharma and CKD Pharmaceuticals Announce Commercialization Agreement for Lorexys™ in South Korea for Treatment of Hypoactive Sexual Desire Disorder (HSDD) in Women
S1 Biopharma
  • COMPANY
    • ABOUT US
    • MANAGEMENT
    • BOARD OF DIRECTORS
    • MEDICAL ADVISORY BOARD
  • PIPELINE
    • OREXA
    • LOREXYS
    • S1B-307
    • S1B-3006
  • A New Vision for addressing Sexual Wellness
    • SEXUAL DYSFUNCTION R&D
    • SCIENTIFIC PUBLICATIONS
    • PARTNERING
  • NEWSROOM
    • PRESS RELEASES
    • MEDIA COVERAGE
  • INVESTORS
    • LOGIN
  • CONTACT US

S1 Biopharma and CKD Pharmaceuticals Announce Commercialization Agreement for Lorexys™ in South Korea for Treatment of Hypoactive Sexual Desire Disorder (HSDD) in Women

Deal advances S1 Biopharma strategy for global commercialization of Lorexys. NEW YORK, Dec. 8, 2015 /PRNewswire/ — S1 Biopharma, Inc. a leading developer of first-in-class drugs for the treatment of sexual dysfunction and hypoactive sexual desire disorder (HSDD) in both women…

Read more ›

Nicolas Sitchon, CEO of S1 Biopharma, to Present at BIO-Europe 2015 Conference

Mr. Sitchon will present an update on S1 Biopharma’s clinical stage development programs targeting treatment of diminished sexual desire in women and men. NEW YORK, Nov. 2, 2015 /PRNewswire/ — S1 Biopharma, Inc., a leading developer of first-in-class drugs for…

Read more ›

Dr. Robert Pyke from S1 Biopharma to Present at ExL Pharma CNS Clinical Trial Forum

Expert on female sexual dysfunction disorder and CNS drug safety to outline challenges in development of combination therapies for CNS disorders. NEW YORK, Oct. 31, 2015 /PRNewswire/ — S1 Biopharma, Inc., a leading developer of first-in-class drugs for the treatment of sexual…

Read more ›

S1 Biopharma Supports FDA Advisory Committee’s Recommendation to Approve the First-Ever Treatment for Hypoactive Sexual Desire Disorder

NEW YORK, June 5, 2015 /PRNewswire/ — Yesterday’s FDA Advisory Committee recommendation for the approval of flibanserin was a landmark step for women’s health, addressing the important unmet medical need for women living with hypoactive sexual desire disorder, or HSDD.…

Read more ›

S1 Biopharma prepares to initiate Phase 2a Clinical Trial for Low Male Sexual Desire

JERSEY CITY, N.J., March 3, 2014 /PRNewswire/ — S1 Biopharma today announced its plan to initiate Phase 2a clinical trials in the third quarter of this year for Orexa (S1P-205), its first-in-class therapy to treat male Hypoactive Sexual Desire Disorder…

Read more ›

Sexual desire and hypoactive sexual desire disorder in women. Introduction and overview. Standard operating procedure (SOP Part 1).

Bitzer J, Giraldi A, Pfaus J. J Sex Med. 2013 Jan;10(1):36-49. doi: 10.1111/j.1743-6109.2012.02818.x. Epub 2012 Sep 13. Link

Hypoactive sexual desire disorder in women: treatment options beyond testosterone and approaches to communicating with patients on sexual health.

Lodise NM. Pharmacotherapy. 2013 Apr;33(4):411-21. doi: 10.1002/phar.1209. Link

Sexual problems and distress in United States women: prevalence and correlates

Shifren JL, Monz BU, Russo PA, Segreti A, Johannes CB. Obstet Gynecol. 2008 Nov;112(5):970-8. Link

The Scientist | Opinion: Sexual Dysfunction Matters

Financial Times | S1 Biopharma starts trial of female libido drug

‹ Older posts
Newer posts ›

  • CONTACT US
  • SITE MAP
  • Terms of Use
  • © S1 biopharma Inc.
S1 Biopharma, Inc.
7 World Trade Center
250 Greenwich St.
46th Floor
New York City, NY 10007
Email: info@s1biopharma.com